Osimertinib: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<scene name='99/999451/Overall/1'>Crystal Structure of EGFR(L858R/T790M/C797S) in complex with Osimertinib</scene> ([[6lud]]). | <scene name='99/999451/Overall/1'>Crystal Structure of EGFR(L858R/T790M/C797S) in complex with Osimertinib</scene> ([[6lud]]). | ||
<scene name='99/999451/Binding_site/1'>Osimertinib binding site</scene>. | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 16:11, 10 October 2023
Osimertinib, sold under the brand name Tagrisso,[1] is a medication used to treat non-small-cell lung carcinomas with specific mutations.[2][3] It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (see Receptor tyrosine kinases). See also Osimertinib. (6lud). .
|
| ||||||||||
ReferencesReferences
- ↑ "Proposed INN: List 113" (PDF). International Nonproprietary Names for Pharmaceutical Substances (INN). 29 (2): 285. 2015. Archived (PDF) from the original on 28 April 2017. Retrieved 16 November 2015
- ↑ Ayeni D, Politi K, Goldberg SB. Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer. Clin Cancer Res. 2015 Sep 1;21(17):3818-20. PMID:26169963 doi:10.1158/1078-0432.CCR-15-1211
- ↑ Tan CS, Gilligan D, Pacey S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 2015 Sep;16(9):e447-e459. PMID:26370354 doi:10.1016/S1470-2045(15)00246-6